Skip to main content

Table 2 Medications administered to patients with Behçet’s disease in the RISE registry

From: Epidemiology and treatment of Behçet’s disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions

Medications Total patients (N = 1323)
No therapy recorded 111 (8.4)
Colchicine 728 (55.0)
Dapsone 62 (4.7)
Glucocorticoids Any prednisone or equivalenta 895 (67.6)
csDMARDs Azathioprine 418 (31.6)
Methotrexate 288 (21.8)
Hydroxychloroquine 117 (8.8)
Sulfasalazine 53 (4.0)
Mycophenolate 31 (2.3)
Leflunomide 26 (2.0)
Cyclosporine 23 (1.7)
Tacrolimus 11 (0.83)
Cyclophosphamide < 10
Minocycline < 10
Biologics-TNFi Infliximab 192 (14.5)
Adalimumab 187 (14.1)
Etanercept 92 (6.9)
Certolizumab 30 (2.3)
Golimumab 20 (1.5)
Biologics-non-TNFib 59 (4.5)
 Targeted small molecules Tofacitinib 11 (0.80)
Baricitinib < 10
Apremilast 42 (3.2)
 Anticoagulants Warfarin 39 (2.9)
Rivaroxaban 27 (2.0)
Apixaban 15 (1.1)
Enoxaparin 11 (0.8)
Dabigatran < 10
Edoxaban 0 (0.0)
  1. RISE Rheumatology Informatics System for Effectiveness, csDMARDs conventional disease modifying anti-rheumatic drugs, TNFi tumor necrosis factor inhibitors
  2. For privacy protection, we reported no cell sizes < 10
  3. aPrednisone or equivalent included prednisone and other oral and intravenous steroids
  4. bBiologics-non-TNFi include rituximab, abatacept, tocilizumab, ustekinumab, anakinra, and secukinumab